$GH

Bell Michael Brian sold $257K of GH

Bell Michael Brian (Chief Financial Officer) sold 2,000 shares of Guardant Health, Inc. (GH) at $128.62 ($0.26M total) on 2026-06-05.

Original reporting
SEC EDGAR · Bell Michael Brian
Published Jun 8, 2026, 10:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, and post-transaction holdings).

02

Market read

Traders may note insider selling as a mild sentiment datapoint, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article does not state whether the sale was for taxes, diversification, or other non-informational reasons; also no 10b5-1 plan is cited, which can cut both ways for interpretation.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-08 (covers sale dated 2026-06-05)

Background

This is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health CFO Michael Brian Bell filed an open-market sale of 2,000 shares at $128.6203 on 2026-06-05 (Form 4).

Expected impact

Low near-term impact; any effect is likely sentiment-only and outweighed by upcoming company-specific catalysts.

Evidence & confidence

The filing is a disclosed open-market sale (no 10b5-1 plan stated) but is not accompanied by new operational/regulatory/financial information.

Market effects

Minimal; single insider sale does not materially change sector risk or read-across.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/taxes and may not reflect bearish fundamentals, especially when not tied to a new negative event.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider transaction; CFO sold shares in an open-market transaction.

  • Michael Brian Bell

    Chief Financial Officer who executed the reported sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.